Endothelial dysfunction in a general practitioner’s work

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Endothelial dysfunction (ED) is a pathological condition that is impairment in the synthesis of endothelial factors and is a major component in the pathogenesis of many diseases, including those of a therapeutic profile. Many specialists now consider ED as a universal component in the development of cardiovascular and respiratory diseases. The paper contains information about the main functions of the endothelium and their impact on the organs and systems of the body, the state of microhemocirculation, and the entire internal environment. It also considers ED that affects vasomotor, hemostatic, adhesive, and angiogenic functions and the main markers of endothelial damage. The possibilities of preventive measures and pharmacological correction of ED are discussed.

全文:

受限制的访问

作者简介

E. Svetlichnaya

Volgograd State Medical University, Ministry of Health of Russia

编辑信件的主要联系方式.
Email: vskvortsov1@ya.ru
俄罗斯联邦, Volgograd

V. Skvortsov

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru

Professor, MD

俄罗斯联邦, Volgograd

B. Levitan

Astrakhan State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru

Professor, MD

俄罗斯联邦, Astrakhan

I. Rodionova

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru

Associate Professor, Candidate of Medical Sciences

俄罗斯联邦, Volgograd

D. Shtonda

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru
俄罗斯联邦, Volgograd

参考

  1. Stepanova T.V., Ivanov A.N., Popykhova E.B. et al. Endotelial'naya disfunktsiya i ee markery. Evraziiskoe nauchnoe ob"edinenie. 2018; 11-2: 120–3 (in Russ.).
  2. Sevket B. Endothelial Dysfunction and Inflammatory Markers of Vascular Disease. Curr Vasc Pharmacol. 2021; 19 (3): 243–9. doi: 10.2174/1570161118666200421142542
  3. Dildar K., Hafize U. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol. 2017; 956: 511–40. doi: 10.1007/5584_2016_90
  4. Vasina L.V., Petrishchev N.N., Vlasov T.D. Markers of endothelial dysfunction. Regional blood circulation and microcirculation. 2017; 16 (1): 4–15 (in Russ.). doi: 10.24884/1682-6655-2017-16-1-4-15
  5. Gozhenko A.I., Kuznetsova H.S., Kuznetsova K.S. et al. Endothelial dysfunction in the pathogenesis of diabetes complications The message I. Endothelial dysfunction: etiology, pathogenesis and diagnostic methods Endokrynologia. 2017; 22 (2): 171–81 (in Russ.).
  6. Petrishchev N.N., Vasina L.V., Vlasov T.D. et al. Tipovye formy disfunktsii endoteliya. Kliniko-laboratornyi konsilium. 2007; 18: 31–5 (in Russ.).
  7. Ryabchenko А.Yu., Dolgov А.М., Denisov Е.N. et al. Role of nitric oxide and endothelin-1 in the development of ischemic disorders of cerebral circulation. Neurology Bulletin. 2014; 1: 34–7 (in Russ.).
  8. Pavlovic R.F., Kocic G., Simonovic D. et al. Effects of Music Therapy on Endothelial Function in Patients With Coronary Artery Disease Participating in Aerobic Exercise Therapy. Altern Ther Health Med. 2017; 23 (3): at5491.
  9. Shishkin A.N., Lyndina M.L. Endothelial dysfunction and hypertension. Arterial’naya Gipertenziya = Arterial Hypertension. 2008; 14 (4): 315–9 (in Russ.). doi: 10.18705/1607-419X-2008-14-4-315-319
  10. Terentieva N.N., Popova M.A. Assessment of endothelial dysfunction with combination of ischemic heart disease and chronic obstructive pulmonary disease. Vestnik SurGU. 2015; 2 (24): 36–9 (in Russ.).
  11. Samoluk M.O., Grigorieva N.Yu. Current understanding of endothelial dysfunction in patients presenting comorbid cardiopulmonary pathology (review). Meditsinskii al'manakh. 2020; 1: 27–9 (in Russ.).
  12. Shurygin M.G., Shurygina I.A., Kanya O.V. et al. Ignificance of the increased production of endothelin in myocardial infarction. Fundamental Research. 2015; 1: 1281–7 (in Russ.).
  13. Chernova E.V. Von Willebrand factor. Herald of North-Western State Medical University named after I.I. Mechnikov. 2018; 10 (4): 73–80 (in Russ.). doi: 10.17816/mechnikov201810473-80
  14. Sokolov E.I., Grishina T.I., Shtin S.R. Effect of von Willebrand factor and endothelin-1 on formation of thrombotic status in patients with ischemic heart disease. Kardiologiya. 2013; 3: 25–30 (in Russ.).
  15. Vlasov T.D., Nesterovich I.I., Shimanski D.A. Endothelial dysfunction: from the particular to the general. Return to the «Old Paradigm»? Regional blood circulation and microcirculation. 2019; 18 (2): 19–27 (in Russ.). doi: 10.24884/1682-6655-2019-18-2-19-27
  16. Olson N.E., Chao S., Lindner V. et al. Intimal smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast growth factor. Am J Pathol. 1992; 140: 1017–23.
  17. Shvangiradze T.A., Bondarenko I.Z., Troshina E.A. et al. Angiotensin II and transforming growth factor β affect cardiovascular and renal disease in patients with type 2 diabetes mellitus: benefits of dpp-4 inhibitors treatment. Obesity and metabolism. 2019; 16 (3): 55–61 (in Russ.). doi: 10.14341/omet10346
  18. Vorobyeva E.N., Vorobуev R.I., Sharlaeva E.A. et al. Endothelial dysfunction in cardiovascular diseases: risk factors, methods of diagnostic, and correction. Acta Biologica Sibirica. 2016; 1: 21–40 (in Russ.). doi: 10.14258/abs.v2i1.1219
  19. Dedov D.V., Mazaev V.P., Ryazanova S.V. et al. Predictors of cardiovascular complications in men with stable coronary heart disease and arterial hypertension. Modern problems of science and education. 2020; 5: 124 (in Russ.). doi: 10.17513/spno.30195

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2023
##common.cookie##